BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 10096544)

  • 1. Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells.
    Murakami M; Gurski KJ; Marincola FM; Ackland J; Steller MA
    Cancer Res; 1999 Mar; 59(6):1184-7. PubMed ID: 10096544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Jayaprabhu S; Pecorelli S; Parham GP; Cannon MJ
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):804s-810s. PubMed ID: 11300476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells.
    De Bruijn ML; Schuurhuis DH; Vierboom MP; Vermeulen H; de Cock KA; Ooms ME; Ressing ME; Toebes M; Franken KL; Drijfhout JW; Ottenhoff TH; Offringa R; Melief CJ
    Cancer Res; 1998 Feb; 58(4):724-31. PubMed ID: 9485027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping of cytotoxic T lymphocytes epitopes in E7 antigen of human papillomavirus type 11.
    Xu Y; Zhu KJ; Chen XZ; Zhao KJ; Lu ZM; Cheng H
    Arch Dermatol Res; 2008 Jun; 300(5):235-42. PubMed ID: 18299861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death.
    Kim JH; Kang TH; Noh KH; Bae HC; Kim SH; Yoo YD; Seong SY; Kim TW
    Immunol Lett; 2009 Jan; 122(1):58-67. PubMed ID: 19135479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of tumor-specific cytotoxic T lymphocytes by stimulation with HPV type 16 E7 peptide-pulsed dendritic cells: an approach to immunotherapy of cervical cancer.
    Schoell WM; Mirhashemi R; Liu B; Janicek MF; Podack ER; Penalver MA; Averette HE
    Gynecol Oncol; 1999 Sep; 74(3):448-55. PubMed ID: 10479508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens.
    Youde SJ; Dunbar PR; Evans EM; Fiander AN; Borysiewicz LK; Cerundolo V; Man S
    Cancer Res; 2000 Jan; 60(2):365-71. PubMed ID: 10667589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
    Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF
    Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7.
    Dell K; Klein C; Gissmann L
    Antivir Ther; 2008; 13(4):495-509. PubMed ID: 18672528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients.
    Valdespino V; Gorodezky C; Ortiz V; Kaufmann AM; Roman-Basaure E; Vazquez A; Berumen J
    Gynecol Oncol; 2005 Jan; 96(1):92-102. PubMed ID: 15589586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer.
    Zehbe I; Kaufmann AM; Schmidt M; Hohn H; Maeurer MJ
    J Immunother; 2007; 30(5):523-32. PubMed ID: 17589293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments.
    Kang TH; Lee JH; Bae HC; Noh KH; Kim JH; Song CK; Shin BC; Hung CF; Wu TC; Park JS; Kim TW
    Immunol Lett; 2006 Aug; 106(2):126-34. PubMed ID: 16844231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector.
    Liu Y; Chiriva-Internati M; Grizzi F; Salati E; Roman JJ; Lim S; Hermonat PL
    Cancer Gene Ther; 2001 Dec; 8(12):948-57. PubMed ID: 11781657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E6 and E7 fusion immunoglobulin from human papilloma virus 16 induces dendritic cell maturation and antigen specific activation of T helper 1 response.
    Kim SH; Hur YJ; Lee SJ; Kim SJ; Park CG; Oh YK; Jung WW; Seo JB; Nam MH; Choi I; Chun T
    Biotechnol Lett; 2011 Apr; 33(4):663-71. PubMed ID: 21140193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic peptides induce a cytotoxic response against human papillomavirus type-18.
    Castellanos MR; Hayes RL; Maiman MA
    Gynecol Oncol; 2001 Jul; 82(1):77-83. PubMed ID: 11426965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition.
    Samorski R; Gissmann L; Osen W
    Immunol Lett; 2006 Sep; 107(1):41-9. PubMed ID: 16949679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
    Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
    Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.
    Ressing ME; Sette A; Brandt RM; Ruppert J; Wentworth PA; Hartman M; Oseroff C; Grey HM; Melief CJ; Kast WM
    J Immunol; 1995 Jun; 154(11):5934-43. PubMed ID: 7538538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.